Pembrolizumab-axitinib for first-line treatment of advanced renal-cell carcinoma

• Autores: Carmen Lucía Muñoz Cid, Andres Sanchez Ruiz, Raquel Claramunt García
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 23, Nº. 1, 2021, págs. 59-62
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The combination pembrolizumab-axitinib has recently been approved for first line treatment of advanced renal-cell carcinoma in adults. According to the pivotal KEYNOTE-426 trial, pembrolizumab-axitinib administered in previously untreated patients with this condition has obtained better efficacy results than sunitinib, with progression-free survival and overall survival being the main variables of the study. The pembrolizumab-axitinib combination has a more toxic safety profile than the alternatives sunitinib and nivolumab + ipilimumab, since the administration is up to progression. Among them, some of the most frequent are hypertension, diarrhea or palmar-plantar erythrodysesthesia. Therefore, the pembrolizumab-axitinib combination has clinical benefit, but with a very high cost, so that to get closer to reasonable levels of cost-effectiveness, a reduction in price would be appropriate